Real‐World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy
In this interim analysis, ARIA-E occurred in 17% of APOE ε4 homozygous patients; no ARIA and no ICH was reported in those on concomitant anticoagulants. Given the rarity of ICH and small number of patients in this analysis being treated with anticoagulants, conclusions cannot be drawn. In the full data set analysis (data cutoff: May 23, 2025), ARIA risk by APOE ε4 status and antithrombotic therapy use will be further explored.
Authors
- Curtis P. Schreiber
- Paul Ernest Schulz (ORCID: https://orcid.org/0000-0003-0676-002X)
- Daryl Jones
- David C. Weisman
- Michael Rosenbloom (ORCID: https://orcid.org/0000-0002-2768-9501)
- Christian Camargo
- Gregory Cooper
- Brooke Allen
- Samuel Giles
- Cara Leahy
- Jose Soria‐Lopez
- Courtney Adams
- Marwan N. Sabbagh
- Martin Sadowski
Institutions
- Allen Institute for Brain Science (US)
- Stone Clinic (US)
- Barrow Neurological Institute (US)
- University of Miami (US)
- Cancer Treatment Centers of America (US)
- Norton Healthcare (US)
- Abington Memorial Hospital (US)
- University of California San Diego (US)
- NYU Langone Health (US)
- Memorial Healthcare System (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Rongsheng Petrochemical (China) (CN)
- Eisai (United States) (US)
- Memorial Hospital (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108603
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00